Patent protection of pharmaceuticals
Konieczny, M.T.
Acta Poloniae Pharmaceutica 57 Suppl: 84-87
2000
ISSN/ISBN: 0001-6837 PMID: 11293276 Document Number: 519959
Patenting of biologically active compounds by academic institutions is discussed, with emphasis on patents for already known compounds.
Document emailed within 1 workday
Related Documents
Halliburton, M. 2009: Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime Global Public Health 4(6): 515-527Pavento, L.C.; Greene, J.L.; McDonald, J.K. 2003: International patent protection for HIV-related therapies: patent attorney's perspective Emory international law review 17(2): 919-931
2009: India refuses patent protection for two key HIV drugs Hiv/Aids Policy and Law Review 14(2): 28-29
Watson, R. 2010: European Commission targets drug firms over illegal patent protection Bmj 340: C268
Gouveia, W.A. 1993: The rising cost of pharmaceuticals: understanding and managing the escalating cost of pharmaceuticals in health care institutions. Executive summary American Journal of Hospital Pharmacy 50(8 Suppl. 4): S2-S3
Lobb, W.B.; Wilkin, N.E.; Holmes, E.R. 2015: Pharmacists' Perceptions of the Economic Value of Compounded Pharmaceuticals: a Comparison of Compounded and Commercial Pharmaceuticals in Select Disease States International Journal of Pharmaceutical Compounding 19(6): 514-520
Halberg, F. 1974: Protection by timing treatment according to bodily rhythms - an analogy to protection by scrubbing before surgery Chronobiologia 1(Suppl 1): 27-72
Pearson, E 2002: Half-hearted protection: What does victim protection really mean for victims of trafficking in Europe? Gender and Development 10(1): 56-59
Rauchwerger, J.M. 1972: Radiation protection by tibia-shielding in adult, weanling and suckling mice. I. Comparative protection studies International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine 22(3): 269-278
Tsuchiya, T. 1980: Radiation protection and recommendation of the international commission on radiological protection Journal of UOEH 2(3): 393-400
2013: Most prescribed pharmaceuticals Modern Healthcare 43(28): 34
Haddad, J.J. 2001: VX-745. Vertex Pharmaceuticals Current Opinion in Investigational Drugs 2(8): 1070-1076
Eder, D.N. 2002: CEE-03-310 CeNeS pharmaceuticals Current Opinion in Investigational Drugs 3(2): 284-288
Lim, M.L. 2001: DPC-083. DuPont Pharmaceuticals Current Opinion in Investigational Drugs 2(9): 1209-1212
Smith, P.F. 2004: GW-1000. GW Pharmaceuticals Current Opinion in Investigational Drugs 5(7): 748-754
Hegde, G.T.; Murali, K.S.; Bhat, D.M.; Bhat, P.R.; Ravindranath, N.H. 2005: Effect of protection on regeneration in some selected village forests under community protection in Uttara Kannada district, Karnataka, India Current Science 88(5): 810-815
Ahsan, S.S.; Blaug, S.M. 1960: Interactions of tweens with some pharmaceuticals Drug Standards 28: 95-100
Waldron, C.J.; Poisal, J.A. 1999: Five most commonly used types of pharmaceuticals Health Care Financing Review 20(3): 119-123
Le Pen, C. 2015: Pharmaceuticals: is there a just price for innovation? La Revue du Praticien 65(9): 1141-1145
Malik, P. 2002: Promises kept and broken: new pharmaceuticals Canadian Journal of Cardiology 18(5): 493-494